Rewiring Of Glucose And Lipid Metabolism Induced By G Protein-Coupled Receptor 17 Silencing Enables The Transition Of Oligodendrocyte Progenitors To Myelinating Cells
Jul 13, 2023
4. Discussion
In recent years, several studies have highlighted the relevance of GPR17 in OL differentiation, validating this receptor not only as a marker of a precise maturation time window (i.e., the O4+ pre-OL intermediate stage), but demonstrating that it also acts as a key regulator of OPC differentiation [12,19]. Notably, during physiological differentiation, after OPC intermediate stages, GPR17 has to be silenced to allow cells’ terminal maturation, an event that likely occurs through both downregulation/internalization of membrane receptor complexes and nuclear repression of gpr17 gene transcription [37,40]. Defective GPR17 silencing, i.e., any conditions leading to persistent GPR17 aberrant expression (such as those observed in several neurodegenerative conditions associated to demyelination), blocks cells at immature stages and contributes to remyelination defects [15,41]. This has led to the hypothesis that the timely GPR17 silencing acts as a “green signal” to promote effective myelination by favoring metabolic and biochemical processes necessary for cell maturation [13]. However, the nature and precise sequela of the events activated by GPR17 silencing is still unknown. Here, we addressed this gap by, first, performing a whole transcriptomic analysis on OPCs under normal conditions and after mimicking GPR17 downregulation by siRNA technology, followed by an analysis of the dataset of differentially expressed genes by pathway- and ontology-based approaches. This initial analysis suggested alterations of various ways and biological processes known for their importance in the maturation of OLs, including the mTOR and Wnt signaling pathways, cytoskeleton remodeling, and regulation of energy and OPC metabolism.

CLICK HERE TO GET CISTANCHE FOR NEURODEGENERATIVE DISEASES
Targeted metabolomic analysis during OPC differentiation and following GPR17 silencing allowed us to get insights into the possible link between GPR17 expression and OPC metabolism. In early OPCs, when GPR17 expression is still physiologically low, cells displayed high levels of metabolites belonging to the Krebs cycle, which were much less abundant at later times, indicating their consumption to produce other key metabolites. This is in line with literature data showing that OPCs are more metabolically active than OLs and that ATP production in rodent OPCs is predominantly dependent on oxidative phosphorylation [7]. At intermediate stages (from DID 1 to DID 3), pre-OLs showed a marked upregulation of molecules involved in fatty acid and cholesterol synthesis, like acetyl-CoA (that represents the precursor of cholesterol and fatty acids) and malonyl-CoA (a specifific intermediate of fatty acid synthesis). These changes perfectly coincided with the timing of GPR17 expression in OPCs, which is very low at day 0, when OPCs are induced to exit the cell cycle and start differentiation, and gradually reaches its maximal expression at DID 3, when pre-OLs have already downregulated metabolites involved in the cell cycle and are upregulating molecules related to fatty acid synthesis. Globally, these data indicate that when GPR17 reaches its maximal expression, pre-OLs mainly use glucose and amino acids to sustain cholesterol and fatty acid biosynthesis. Of note, it is known that, despite aerobic glycolysis generating ATP with less efficiency than oxidative phosphorylation, it produces the carbon chain precursors necessary to support protein and lipid biosynthesis for myelin production [42], limits the production of ROS, and promotes the production of long-lived lipids required by OL myelin [7]. We also observed decreased levels of AMP and ADP from day 0 to DID 5 and a transient increase of ATP between DID 1 and 3. These data are fully compatible with GPR17 expression and its consolidated role in regulating (in concert with other GPCRs) the intracellular production of cyclic AMP (cAMP) from ATP during OL differentiation [13,43,44]. When GPR17 expression starts rising (DID 1 to 3), endogenous ligands promote a gradual increase of the activity of the receptor-coupled Gi protein, that, in turn, reduces the production of cAMP [12], thus resulting in increased intracellular levels of ATP (here acting as the substrate of adenylyl cyclase for cAMP synthesis), concomitantly with the increased levels of lipid biosynthesis metabolites (acetyl-CoA and malonylCoA). These data are also in line with the concept that anabolic metabolism (such as lipid synthesis) usually occurs in favorable energy status.

After GPR17 silencing, results from our metabolomic analysis suggest an extensive rewiring of OPC metabolism. We observed changes in the abundance of intermediates of the Krebs cycle, such as fumarate, malate, and citrate (the starting substrate for the synthesis of lipids and cholesterol) and of other metabolites described in the literature for their critical role in OL survival and differentiation, as well as in myelin synthesis, such as creatine, taurine and lactate [39,45,46]. Despite these alterations all being potentially interesting, we decided to focus our analyses on the role of lactate, based on previous data implicating it in OL cellular metabolism, differentiation and myelination [4,47], as well as in communication with nearby neurons and glia [48]. Analysis of intracellular lactate abundance during OPC physiological differentiation showed kinetics following that of GPR17 (high levels at intermediate stages, low levels during the initial and final stages), whereas after GPR17 silencing, lactate levels decreased prematurely, reaching a minimum at intermediate stages. The relationship between GPR17 expression and lactate abundance has previously been observed in recent studies, where an increase in glycolysis and lactate production, secondary to the alteration of the cAMP-PKA-PDK1 axis, has been found in OLs deriving from GPR17 knock-out animals [49]. According to this, our microarray analysis on GPR17-silenced OPCs demonstrated the upregulation of genes associated to glycolysis and lactate production (PFK, PDK1, LDH); however, on the other hand, our metabolic data showed a reduction in lactate intracellular levels. To shed light on these apparently contrasting results, we evaluated the release of this metabolite in the culture media. Increased lactate levels were found at the same times at which lowered lactate concentrations were found in cells’ cytoplasm, suggesting the release of this metabolite extracellularly, and that GPR17 in OLs could play an important role in the transport of energy metabolites to neuronal cells. This hypothesis is corroborated by a recent finding showing that, in GPR17 knockout mice, increased lactate levels in the environment of hypothalamic neurons can modulate neuronal activity through activation of the AKT and STAT3 pathways [49]. Based on this evidence, we speculate that a similar mechanism could apply to taurine and creatine, which are known to positively regulate the myelination process [45,46], and whose intracellular levels are indeed reduced in GPR17-silenced OPCs. Of note, it has been shown that neurons do not express the enzymes responsible for the synthesis of these metabolites, suggesting that they can only derive from neighboring glial cells [50,51].
The ability of OLs to import lactate or release it extracellularly is mediated by monocarboxylate transporter 1 (MCT1), responsible for the passive transport of lactate and hydrogen towards the cytoplasm or the extracellular environment in response to its concentrations in the two compartments [47,52]. Despite in vivo observations indicating that the lack of MCT1 in OLs and their progenitors in the early post-natal period and in early adulthood does not affect myelination, possibly due to the availability of other energy intermediates such as glucose, during adulthood, loss of MCT1 leads to axonopathy and hypo-myelination, demonstrating the essential role that monocarboxylic acids play in the energetic homeostasis of OLs [53]. In our study, the increase in extracellular lactate observed after GPR17 silencing was associated to accelerated maturation, raising the possibility that lactate released by mature OLs can be taken up by immature OLs to enhance their maturation in an autocrine fashion. To assess this hypothesis, we blocked lactate release by exposing GPR17-silenced OPCs to a selective MCT1 inhibitor. Reduction of lactate efflux indeed resulted in decreased OPC maturation, suggesting that GPR17 downregulation could foster the release of lactate extracellularly, thus propagating the maturation process to nearby cells. Accordingly, recent studies have shown that lactate can directly promote the cell cycling rate and differentiation of OPCs [39].

The expression changes observed after GPR17 silencing also suggested a potential link between GPR17 expression and the activation of lipid and cholesterol synthetic pathways. Among the most relevant changes, we found an increased expression of LXRα and its target genes, SREBP1c, ABCG1, and ABCA1. The ability of LXRα to promote cell differentiation in OLs has been demonstrated in vivo following lysolecithin-induced demyelination: LXRα activation by both natural (i.e., oxysterols) and synthetic agonists promoted remyelination of areas affected by demyelinating injury [54]. Oxysterols are also pro-inflammatory molecules capable of activating several G protein-coupled receptors, including GPR17 [55], whose ability to respond to emergency signals related to oxidative stress, neuro inflammation, and neurodegeneration is widely known. Expression changes of the transcription factors described above are also necessary for the reorganization of lipid metabolism that occurs during the maturation of OLs [56], allowing these cells to increase the synthesis of specifific lipid classes and gradually change the composition of their plasma membrane [2]. This shift characterizes the transition from OPCs to mature OLs; for example, it has been shown that some myelin-specific glycosphingolipids start to be produced in the proximity of terminal differentiation and are maintained in mature myelinating OLs [57]. Our lipidomic data suggest that GPR17 expression may directly influence the abundance of myelin-specific lipids, such as ceramides and sphingomyelins. The correct balance between synthesis and degradation of sphingolipids has been shown to play a critical role in maintaining myelin integrity [58,59]. Moreover, we detected that GPR17 knockdown at DID 5 led to decreased levels of several diacyl-PCs and diacyl-Pes, which are the main species represented in the myelin membrane as reported in the literature [60–62]. The finding that these lipids may play a role in stabilizing the intro period line of myelin [61] further supports the key role of GPR17 as a key player in determining myelin composition and function. Despite decreased levels of diacyl-PCs and diacyl-PEs, we also found increased levels of several plasmalogens (i.e., acyl-alkyl-PC) upon GPR17 depletion at DID5. These PC-derived plasmalogens have been proposed as protective agents in myelin since they prevent membrane lipid peroxidation by reactive oxygen species [63,64]. The protecting effects of plasmalogens has been ascribed to the hydrogen atom adjacent to the vinyl ether bond. Indeed, this hydrogen atom can be more susceptible to oxidation with respect to the ester linkage present in diacyl-PCs and diacyl-PEs [63,64]. Furthermore, myelin plasmalogens participate in membrane formation and/or in maintenance [65,66]. Based on our results, we infer that GPR17 is also important in regulating the balance between diacyl-PC and diacyl-PE and their respective plasmalogens to ensure the optimal structure and function of myelin. However, it should be considered that plasmalogens might be increased without GPR17 as a protective mechanism given their antioxidant role. Alteration in myelin lipids has been also described in diabetic rats [62], underlying a link between glucose metabolism and myelination. It has been reported that diseases characterized by dysregulation of lipid or glucose metabolism (i.e., dyslipidaemias and diabetes) are linked to higher MS risk [67,68], even though the exact pathogenetic mechanisms linking these metabolic dysfunctions to MS are still largely debated. Moreover, the mass spectrometric analysis revealed an increased abundance of phospholipids and a reduction in sphingolipid content in the normal-appearing white matter (NAWM) of subjects with active MS [69], suggesting that specifific metabolic alterations may appear before the onset of demyelinating lesions. Of note, in a previous study, we have shown that the NAWM of MS patients presents the highest abundance of GPR17-expressing cells compared to MS lesions and to the WM of healthy subjects [20].

Our study is the first to show the involvement of GPR17 downregulation in rewiring OPC metabolism during differentiation, but some limitations/caveats should be taken into account. First, in this study, we used primary cultures, which in comparison to cell lines have both advantages and disadvantages. Despite primary OLs being more prone to reach the myelinating stage, data obtained using these cells may have higher variability, due to the fact that OPCs are not synchronized and therefore they follow slightly different maturation kinetics in vitro between independent experiments. However, to tackle this issue, we applied a method of analysis that identifies samples deviating in their metabolomic profile from other samples of the same group, allowing the reallocation to the proper group. Second, we used a targeted metabolomic approach that allowed us to gather several metabolite levels and changes in representative metabolic pathways. As such, a comprehensive untargeted metabolomic analysis (with no a priori definition of metabolites to be detected) can be further informative of other metabolites not considered in our targeted metabolomics, thus generating novel working hypotheses in the field. Third, although our study represents a signifificant advance in understanding the role of GPR17 in OPC maturation, further work remains necessary to assess the relevance of the metabolic changes induced by its downregulation in pathological conditions. In this context, future studies will be aimed at assessing whether GPR17 modulation can be exploited to improve OL metabolism during demyelination/remyelination dynamics in animal models of MS and whether GPR17 dysregulation may correlate with specifific metabolic alterations in human MS lesions and in the NAWM.
Taken together, our results suggest that the GPR17 receptor may act as a checkpoint necessary to inhibit precocious myelination and maintain cells’ reactivity to extracellular signals and highlight the involvement of GPR17 downregulation in the coordination of energy and lipid metabolism rearrangements required for OPC maturation, providing essential hints on the bioactive metabolites and lipids regulated by the receptor. Based on our previous data on alterations of GPR17 expression in MS pathogenesis and remyelination failure, we suggest that these functional and mechanistic insights may inspire new pharmacological and therapeutic approaches for the cure of neurodegenerative diseases.
References
1. Butt, A.M.; Papanikolaou, M.; Rivera, A. Physiology of Oligodendroglia. Adv. Exp. Med. Biol. 2019, 1175, 117–128. [CrossRef] [PubMed]
2. Nave, K.A.; Werner, H.B. Myelination of the nervous system: Mechanisms and functions. Annu. Rev. Cell Dev. Biol. 2014, 30, 503–533. [CrossRef] [PubMed]
3. Narine, M.; Colognato, H. Current Insights Into Oligodendrocyte Metabolism and Its Power to Sculpt the Myelin Landscape. Front. Cell. Neurosci. 2022, 16, 892968. [CrossRef]
4. Tepavcevic, V. Oligodendroglial Energy Metabolism and (re)Myelination. Life 2021, 11, 238. [CrossRef] [PubMed]
5. Rao, V.T.S.; Khan, D.; Cui, Q.L.; Fuh, S.C.; Hossain, S.; Almazan, G.; Multhaup, G.; Healy, L.M.; Kennedy, T.E.; Antel, J.P. Distinct age and differentiation-state dependent metabolic profifiles of oligodendrocytes under optimal and stress conditions. PLoS ONE 2017, 12, e0182372. [CrossRef]
6. Schoenfeld, R.; Wong, A.; Silva, J.; Li, M.; Itoh, A.; Horiuchi, M.; Itoh, T.; Pleasure, D.; Cortopassi, G. Oligodendroglial differentiation induces mitochondrial genes and inhibition of mitochondrial function represses oligodendroglial differentiation. Mitochondrion 2010, 10, 143–150. [CrossRef]
7. Rone, M.B.; Cui, Q.L.; Fang, J.; Wang, L.C.; Zhang, J.; Khan, D.; Bedard, M.; Almazan, G.; Ludwin, S.K.; Jones, R.; et al. Oligodendrogliopathy in Multiple Sclerosis: Low Glycolytic Metabolic Rate Promotes Oligodendrocyte Survival. J. Neurosci. 2016, 36, 4698–4707. [CrossRef]
Ask for more:
Email:wallence.suen@wecistanche.com
Whatsapp/Tel:+86 15292862950
SHOP:
https://www.xjcistanche.com/cistanche-shop






